Clinical Trial

Evaluate Efficacy and Safety of Repeat Subcutaneous Doses of FB825 in Adults With Moderate-to-Severe Atopic Dermatitis

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a randomized, placebo-controlled and double-blind study to evaluate the efficacy, pharmacokinetics, and Safety of repeat subcutaneous doses of FB825 in adults with moderate-to-severe atopic dermatitis.
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2024-04-30; most recent amendment 2026-06-12.
Status change: Not Yet Recruiting → Recruiting 2024-09-11
Trial Details
NCT Number NCT06397911
Lead Sponsor Oneness Biotech Co., Ltd.
Conditions Atopic Dermatitis
Enrollment 114 participants
Start Date 2024-08-08
Primary Completion 2027-05-31 (estimated)
Study Completion 2027-05-31 (estimated)
Updated on ClinicalTrials.gov 2026-06-15